Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.

Saivaishnavi Kamatham,Dorin T. Colibaseanu,Amit Merchea,Faisal Shahjehan,Jason Scott Starr,Kabir Mody,Pashtoon Murtaza Kasi

Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.

2019

Saivaishnavi Kamatham
Dorin T. Colibaseanu
Amit Merchea
Faisal Shahjehan
Jason Scott Starr
Kabir Mody
Pashtoon Murtaza Kasi

e15066Background: Circulating cell-free tumor-DNA (ctDNA) testing (‘liquid biopsy’) is increasingly being employed both in clinical trials as well as clinical practice. We aimed to contrast and com...

Keywords:

Clinical trial
Internal medicine
Liquid biopsy
Oncology
Medicine
MISMATCH REPAIR DEFICIENCY
Surrogate endpoint
Colorectal cancer
cell free
Immunotherapy
Microsatellite instability

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations